Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) designed for acute and long-term use in the management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of acute pain.
ANI Pharmaceuticals president and chief executive officer Arthur Przybyl said: "We are pleased to announce the launch of our second product from the portfolio of approved generic products we acquired from Teva in January 2014."
According to IMS Health, the US market for Etodolac 300mg capsules totals $9m on a trailing 12 month basis.
The company is focused on developing, manufacturing and marketing branded and generic prescription pharmaceuticals.
Currently, the company’s targeted areas of product development include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.